DalCor Pharmaceuticals Alternatives & Competitors
12 companies similar to DalCor Pharmaceuticals — Pioneering Pharmacogenetic Precision Medicine for Cardiovascular Disease
Companies similar to DalCor Pharmaceuticals
Prolocor
Advancing patient care by empowering physicians with effective precision diagnostics for c...
Renovacor
Advancing transformative therapies for cardiovascular disease
Mirnext
Pioneering the future of cardiovascular health with innovative miRNA biomarkers to enhance...
Clinical Pharmacogenetics Implementation Consortium
An international consortium interested in facilitating the use of pharmacogenetic tests fo...
Rival Readout
Competing with DalCor Pharmaceuticals? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Acthera Therapeutics Ltd.
Targeted drug delivery with Hard-Shelled Liposomes, to improve the outcome of stroke and h...
Ariel Precision Medicine
Focused on transforming discoveries into treatments for chronic diseases with high unmet n...
AVROBIO
Clinical-stage lentiviral gene therapy company, powered by plato®. Our vision: bring perso...
CryoTherapeutics SA
Using cryotherapy to stabilize vulnerable plaque and reduce the risk of heart attack
CardioDx
Empowering personalized cardiovascular care through advanced genomic diagnostics.
Franklin by QIAGEN
Franklin harnesses the power of its community to enable actionable insights, serving profe...
GENinCode Predictive Genetics
Clinical Genetics and Precision Medicine. Safeguarding your future health.
Multiomic Health
AI-Enabled Precision Medicine for Cardiovascular Renal Metabolic (CRM) Disease
About DalCor Pharmaceuticals
DalCor Pharmaceuticals, founded in 2015 and headquartered in Canada, is making notable strides in the Health Care and Pharmaceutical industries. Their endeavor, epitomized by the slogan “Pioneering Pharmacogenetic Precision Medicine for Cardiovascular Disease,” underscores their focus on precision medicine targeting ca...
development of precision medicine for cardiovascular diseases, conducting clinical trials, genotype-based therapy research
patients with post-acute coronary syndrome, individuals with AA genotype in ADCY9 gene, healthcare providers
Precision Medicine, Cardiovascular Disease, Pharmacogenetic, Genetic Marker, Dalcetrapib, CETP Inhibitor, Pharmacogenomics, Clinical Insights, Myocardial Infarction, Acute Coronary Syndrome, Genetic Subset, Cardiovascular Events, Pharmaceuticals, Roche, ADCY9 Gene
B2B, B2G
Product Sales, Licensing, Value Based Pricing
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around DalCor Pharmaceuticals: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at DalCor Pharmaceuticals on 12 Sep 2024. The 12 companies listed here were last checked between 26 Jul 2024 and 15 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.